qp0ferbq

Property	Value
?:abstract	OBJECTIVE: The intravitreal injection (IVI) of pharmacological agents is the most commonly performed ocular procedure and is associated with a host of complications. The majority of IVI-related complications data is derived from randomized controlled clinical trials, which report a high adverse event rate. The nature of these protocol-driven trials limit their applicability to the diverse circumstances seen in routine clinical practice. The goal of this study is to determine the prevalence of patient reported IVI-related complications, their risk factors, and the manner in which patients presented in a tertiary eye care center. DESIGN: A retrospective, IRB-approved review. SUBJECTS, PARTICIPANTS AND/OR CONTROLS: 44,734 injections in 5,318 unique patients at the Cleveland Clinic Cole Eye Institute from 2012-2016. METHODS, INTERVENTION, OR TESTING: Intravitreal injection. MAIN OUTCOME MEASURES: Complication occurrence within 15 days of injection. RESULTS: From 2012-2016, a total of 44,734 injections were performed in 5,318 unique patients. Overall, complication rates were low, representing 1.9% of all injections, with 1031 unique complications in 685 (12.9%) patients. The most common minor complications, or those not requiring intervention, were irritation (n=312) and subconjunctival hemorrhage (n=284). The most common serious complications, or those requiring intervention, were corneal abrasion (n=46) and iritis (n=31). The majority of complications (66%) were adequately managed by a telephone/Epic electronic message encounter only. Importantly, no injection protocol parameter, such as type of anesthesia, preparation, or post-injection medication, increased the risk of a complication. However, patient sex, age, number of previous injections, and provider strongly influenced the risk of patient-reported complications. CONCLUSIONS: Overall, complication rates seen in routine clinical practice were low compared to clinical trial reporting. Providers should feel confident in the safety and administration of IVI during times when follow-up office visits and resources may be limited. When performing an IVI, factors such as a patient’s sex, age, number of previous injections, and provider must be taken into account to ensure the best possible outcomes.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/qp0ferbq_hasAnnotation_C0009566> <https://research.tib.eu/covid-19/entity/qp0ferbq_hasAnnotation_C0010032> <https://research.tib.eu/covid-19/entity/qp0ferbq_hasAnnotation_C0038534> <https://research.tib.eu/covid-19/entity/qp0ferbq_hasAnnotation_C0877248> <https://research.tib.eu/covid-19/entity/qp0ferbq_hasAnnotation_C1254351>
?:creator	<https://research.tib.eu/covid-19/entity/Ramos%2C_Michael_S.%3B_Xu%2C_Lucy_T.%3B_Singuri%2C_Srinidhi%3B_Castillo_Tafur%2C_Julio_C.%3B_Arepalli%2C_Sruthi%3B_Ehlers%2C_Justis_P.%3B_Kaiser%2C_Peter_K.%3B_Singh%2C_Rishi_P.%3B_Rachitskaya%2C_Aleksandra_V.%3B_Srivastava%2C_Sunil_K.%3B_Sears%2C_Jonathan_E.%3B_Schachat%2C_Andrew_P.%3B_Babiuch%2C_Amy_S.%3B_Sharma%2C_Sumit%3B_Martin%2C_Daniel_F.%3B_Lowder%2C_Careen_Y.%3B_Singh%2C_Arun_D.%3B_Yuan%2C_Alex%3B_Nowacki%2C_Amy_S.>
?:doi	<https://research.tib.eu/covid-19/entity/10.1016/j.oret.2020.09.024>
?:doi	10.1016/j.oret.2020.09.024
?:journal	Ophthalmol_Retina
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/ebbab10f776ec8b185339dd84d7f4478a244a95d.json
?:pmc_json_files	document_parses/pmc_json/PMC7548755.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7548755>
?:pmid	<https://research.tib.eu/covid-19/entity/33059077.0>
?:pmid	33059077.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:sha_id	<https://research.tib.eu/covid-19/entity/ebbab10f776ec8b185339dd84d7f4478a244a95d>
?:source	Elsevier; Medline; PMC
?:title	Patient-reported complications after intravitreal injection and their predictive factors
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-10-12

Property

Value

?:abstract

OBJECTIVE: The intravitreal injection (IVI) of pharmacological agents is the most commonly performed ocular procedure and is associated with a host of complications. The majority of IVI-related complications data is derived from randomized controlled clinical trials, which report a high adverse event rate. The nature of these protocol-driven trials limit their applicability to the diverse circumstances seen in routine clinical practice. The goal of this study is to determine the prevalence of patient reported IVI-related complications, their risk factors, and the manner in which patients presented in a tertiary eye care center. DESIGN: A retrospective, IRB-approved review. SUBJECTS, PARTICIPANTS AND/OR CONTROLS: 44,734 injections in 5,318 unique patients at the Cleveland Clinic Cole Eye Institute from 2012-2016. METHODS, INTERVENTION, OR TESTING: Intravitreal injection. MAIN OUTCOME MEASURES: Complication occurrence within 15 days of injection. RESULTS: From 2012-2016, a total of 44,734 injections were performed in 5,318 unique patients. Overall, complication rates were low, representing 1.9% of all injections, with 1031 unique complications in 685 (12.9%) patients. The most common minor complications, or those not requiring intervention, were irritation (n=312) and subconjunctival hemorrhage (n=284). The most common serious complications, or those requiring intervention, were corneal abrasion (n=46) and iritis (n=31). The majority of complications (66%) were adequately managed by a telephone/Epic electronic message encounter only. Importantly, no injection protocol parameter, such as type of anesthesia, preparation, or post-injection medication, increased the risk of a complication. However, patient sex, age, number of previous injections, and provider strongly influenced the risk of patient-reported complications. CONCLUSIONS: Overall, complication rates seen in routine clinical practice were low compared to clinical trial reporting. Providers should feel confident in the safety and administration of IVI during times when follow-up office visits and resources may be limited. When performing an IVI, factors such as a patient’s sex, age, number of previous injections, and provider must be taken into account to ensure the best possible outcomes.

is ?:annotates of